Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics
MWN-AI** Summary
Waters Corporation has introduced the Xevo Charge Detection Mass Spectrometer (CDMS), a groundbreaking technology designed to enhance the analysis and development of next-generation biotherapeutics. As the biopharmaceutical landscape evolves, particularly with the growth of cell and gene therapies, the need for advanced analytical tools becomes essential. The Xevo CDMS addresses the challenges posed by the increasing complexity of biomolecules, achieving unprecedented measurement capabilities for molecules exceeding 150 megadaltons (MDa).
This innovative system enables direct mass measurement of individual particles, allowing researchers to analyze protein complexes, nucleic acids, and viral vectors with remarkable precision. One of its notable features is the ability to differentiate between various states of viral vector capsids (empty, partial, full, and overfull) in less than ten minutes per sample, significantly reducing sample volume requirements by up to 100 times compared to traditional methods.
Dr. Udit Batra, Waters’ President and CEO, believes that the XEvo CDMS will catalyze advancements in genetic medicine, facilitating earlier and more accurate characterization of large molecules essential for therapeutic development. This capability is particularly vital for ensuring the safety and efficacy of therapeutics aimed at addressing critical health issues such as cardiovascular diseases and Alzheimer's.
Underpinning this novel technology is the Electrostatic Linear Ion Trap (ELIT), which was developed through collaboration with Indiana University researchers. Waters acquired the technology to speed up its commercialization, making it a pivotal part of their strategy to support the analytical needs of contemporary biopharmaceutical research and regulatory processes.
Available now, the Xevo CDMS, supported by the GxP-ready waters_connect™ software, represents a significant breakthrough in mass spectrometry, promising to elevate the standards of biotherapeutic analysis and development.
MWN-AI** Analysis
The recent introduction of Waters Corporation's Xevo Charge Detection Mass Spectrometer (CDMS) marks a pivotal advancement in the bioanalytical landscape, particularly for the biotech industry focusing on next-generation biotherapeutics. With an ability to analyze mega-mass biomolecules—up to 150+ MDa—this cutting-edge technology provides detailed mass characterization of intricate proteins, nucleic acids, and viral vectors, addressing a significant gap in the current market of analytical instruments.
For investors considering opportunities in this sector, it is crucial to recognize the impact of Waters’ innovation on the accelerating demand for gene and cell therapies, particularly for conditions with high unmet medical needs such as cardiovascular diseases and Alzheimer's. The Xevo CDMS's superior sensitivity and reduced sample volume requirements can streamline research and development processes, enabling faster turnaround times in therapeutic discovery and regulatory approval phases.
Moreover, Waters' strategic acquisition of key technology assets from Indiana University demonstrates their commitment to maintaining a competitive edge in mass spectrometry. The integration of electrostatic linear ion trap technology allows for quicker, more accurate analyses without the cumbersome deconvolution processes traditionally associated with complex biomolecule studies. This can significantly enhance throughput and cost efficiency, making Waters a valuable player in the biotech supply chain.
As the market for biologics continues to expand, driven by rising healthcare demands and innovations in therapeutics, Waters Corporation's latest offering positions it favorably against competitors who may not yet have adopted such advanced analytical tools. Therefore, investors should consider accumulating shares of Waters (NYSE: WAT) as the company is likely to experience notable growth, fueled by the increased reliance on sophisticated analytical solutions in drug development. This move could yield substantial returns in line with the industry's trajectory towards advanced biotherapeutics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Headlines:
- Xevo™ CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.1
- Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between empty, partial, full, and overfull viral vector capsids in less than 10 minutes per sample.2
- Decreases sample volumes by 100 times vs. current methods for assessing cells and nucleic acids.3
MILFORD, Mass., Oct. 13, 2025 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterization for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology. With the rapid growth of cell and gene therapies, mRNA, and complex protein therapeutics, scientists face significant challenges in analyzing increasingly large and heterogeneous drug modalities – yet existing tools are limited in resolution, sensitivity, and compliance-readiness. The Xevo CDMS System addresses these gaps with direct, individual-particle mass measurement for molecules up to 150+ MDa, enabling previously unattainable analysis of protein complexes, nucleic acids, lipid nanoparticles, viral vectors, and more.
"Waters continues to make strategic investments in large molecules, recognizing that advanced tools for bioanalytical characterization play a critical role in driving therapeutic breakthroughs. Today, we are proud to introduce the first-of-its-kind Xevo Charge Detection Mass Spectrometer, enabling the precise analysis of previously unmeasurable molecules," said Udit Batra, Ph.D., President and Chief Executive Officer, Waters Corporation. "We believe the Xevo CDMS will accelerate the global development of genetic medicines and other advanced modalities by providing a greater understanding of the characteristics of large molecules earlier in development, which is crucial for making life-changing therapies more accessible to patients."
The Waters Xevo CDMS provides confident analysis of new modalities, like empty, partial, and full viral vector capsids, using up to 100-fold less sample volume than that required by current techniques, and delivering results in less than ten minutes, even at concentrations as low as 1010 vp/mL. This new capability paves the way for real-time characterization of gene therapies during process development – ultimately improving the safety and efficacy of advanced therapies. Additionally, CDMS absolves the need for deconvolution or digestion approaches to achieve simple and accurate analysis of complex molecules. This transformational mass spectrometry advancement supports a wide range of applications – from discovery and research, through process development, to regulatory approval and manufacturing.
"Our mission is to accelerate the development of gene therapies for genetically mediated cardiovascular diseases and Alzheimer's, where there is a significant unmet need in treatment options," said Timothy Fenn, Ph.D., Vice President, Analytical Development and Quality Control, Lexeo Therapeutics. "With CDMS, we're asking questions we didn't know we could ask. It's a game-changer for our analytical workflows, enabling us to generate accurate, reproducible results in minutes."
At the heart of the Xevo CDMS is the Electrostatic Linear Ion Trap (ELIT), which provides direct measurement of individual ions through simultaneous measurement of their mass-to-charge ratio and mass. The novel technology was developed by Indiana University and Megadalton Solutions, founded by Distinguished Professors Martin Jarrold and David Clemmer at Indiana University. Waters acquired the technology assets and intellectual property rights of Indiana University in 2022 to accelerate its path to commercialization.
The Waters Xevo CDMS System is powered by the GxP-ready waters_connect™ Software and is available to order now.
ABOUT: Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science.
Waters, Xevo, and waters_connect are trademarks of Waters Technologies Corporation.
Additional Resources:
Contact:
Molly Gluck
Head of External Communications
Waters Corporation
molly_gluck@waters.com
Mobile: +1.617.833.8166
References:
1 Demonstrated?mass?analysis on-instrument of various molecular species from <100 kDa to Chikungunya Virus complexes of >150?MDa.?
2 Time taken to acquire a statistically representative number of ions to enable characterization of AAV features.
3 Indicative of amount of sample required for sample preparation. Actual sample consumed during analysis is <5 µL.
SOURCE Waters Corporation
FAQ**
How does the introduction of the Xevo Charge Detection Mass Spectrometer (CDMS) by Waters Corporation WAT position the company in the competitive landscape of biotherapeutics and mass spectrometry technology?
What specific advantages does the Xevo CDMS offer over existing mass spectrometry techniques, and how might these advantages impact the workflow of researchers developing next-generation biotherapeutics at Waters Corporation WAT?
Considering the technology's ability to analyze large and heterogeneous biomolecules, how could the Xevo CDMS influence the timeline and success rates of clinical trials in therapeutics developed by Waters Corporation WAT?
With the acquisition of the ELIT technology developed by Indiana University, what are Waters Corporation WAT's strategic plans to leverage this innovation for further advancements in biotherapeutic analysis?
**MWN-AI FAQ is based on asking OpenAI questions about Waters Corporation (NYSE: WAT).
NASDAQ: WAT
WAT Trading
-1.01% G/L:
$284.73 Last:
349,636 Volume:
$285.48 Open:
